AstraZeneca shares fall on study data, competition
Shares of drug developer AstraZeneca fell Wednesday after the company reported mixed study results from its developing lung cancer treatment Zactima and as it faces new generic competition to its asthma drug Pulmicort.
This entry was posted on Wednesday, November 19th, 2008 at 4:03 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.